Cargando…
ARNI in HFrEF—One-Centre Experience in the Era before the 2021 ESC HF Recommendations
Background: Sacubitril/valsartan, an angiotensin receptor–neprilysin inhibitor (ARNI), has demonstrated a survival benefit and reduces heart failure hospitalization in patients with heart failure with reduced left ventricular ejection fraction (HFrEF); however, our experience in this field is limite...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8872461/ https://www.ncbi.nlm.nih.gov/pubmed/35206278 http://dx.doi.org/10.3390/ijerph19042089 |